In the wake of the Scandinavian Simvastatin Survival Study trial.

IF 4.6 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current opinion in lipidology Pub Date : 2025-08-08 DOI:10.1097/MOL.0000000000001008

Timo E Strandberg

{"title":"In the wake of the Scandinavian Simvastatin Survival Study trial.","authors":"Timo E Strandberg","doi":"10.1097/MOL.0000000000001008","DOIUrl":null,"url":null,"abstract":"Purpose of review: In 1994, the 4S trial was revolutionary by showing that cholesterol lowering with simvastatin reduced, not only atherosclerotic vascular disease (ASCVD) events, but also all-cause mortality as compared to placebo. During the following 30 years, statins have proved to be well tolerated and effective and also paved way for new innovations in the field of dyslipidaemia therapy.Recent findings: The aim of this review is to summarize current knowledge about statins and effects of cholesterol-lowering accumulated in the wake of 4S trial: both vascular and nonvascular benefits, adverse effects, adherence, and statin intolerance. While secondary prevention of ASCVD has emphasized 'the lower the better' in LDL-cholesterol lowering, emerging topic is 'the longer the better' to reduce lifetime LDL burden and achieve full potential of ASCVD prevention. With statins as backbone therapy, new treatment innovations are in trials to better manage all atherosclerotic lipoproteins and residual risk.Summary: After becoming generic, statins are inexpensive and well tolerated therapy with potential to substantially reduce the burden of atherosclerotic vascular disease world-wide. To achieve these goals, both accessibility and adherence are fundamental issues.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000001008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: In 1994, the 4S trial was revolutionary by showing that cholesterol lowering with simvastatin reduced, not only atherosclerotic vascular disease (ASCVD) events, but also all-cause mortality as compared to placebo. During the following 30 years, statins have proved to be well tolerated and effective and also paved way for new innovations in the field of dyslipidaemia therapy.

Recent findings: The aim of this review is to summarize current knowledge about statins and effects of cholesterol-lowering accumulated in the wake of 4S trial: both vascular and nonvascular benefits, adverse effects, adherence, and statin intolerance. While secondary prevention of ASCVD has emphasized 'the lower the better' in LDL-cholesterol lowering, emerging topic is 'the longer the better' to reduce lifetime LDL burden and achieve full potential of ASCVD prevention. With statins as backbone therapy, new treatment innovations are in trials to better manage all atherosclerotic lipoproteins and residual risk.

Summary: After becoming generic, statins are inexpensive and well tolerated therapy with potential to substantially reduce the burden of atherosclerotic vascular disease world-wide. To achieve these goals, both accessibility and adherence are fundamental issues.

查看原文本刊更多论文

在斯堪的纳维亚辛伐他汀生存研究试验之后。

回顾目的：1994年，4S试验是革命性的，它表明与安慰剂相比，辛伐他汀降低胆固醇不仅减少了动脉粥样硬化性血管疾病（ASCVD）事件，而且降低了全因死亡率。在接下来的30年里，他汀类药物被证明具有良好的耐受性和有效性，也为血脂异常治疗领域的创新铺平了道路。最新发现：本综述的目的是总结4S试验后积累的有关他汀类药物和降胆固醇作用的最新知识：血管和非血管益处、不良反应、依从性和他汀类药物不耐受。虽然ASCVD二级预防强调降低LDL-胆固醇“越低越好”，但新出现的主题是“越长越好”，以减少终生LDL负担，充分发挥ASCVD预防的潜力。以他汀类药物为主要疗法，新的治疗创新正在试验中，以更好地控制所有动脉粥样硬化脂蛋白和剩余风险。摘要：在成为通用药物后，他汀类药物是一种廉价且耐受性良好的治疗药物，具有在全球范围内显著减轻动脉粥样硬化性血管疾病负担的潜力。为了实现这些目标，可及性和依从性都是基本问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in lipidology 医学-内分泌学与代谢

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.